Public Meeting on the Reauthorization of the Biosimilar User Fee Act (BsUFA) - 11/19/2020 - 11/19/2020

The Food and Drug Administration (FDA or Agency) is announcing a public meeting on the reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years (FYs) 2023 through 2027.

Source: FDA Center for Drug Evaluation and Research - What's New - September 29, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news